Perjeta: new option for HER2-positive breast cancer

Perjeta (pertuzumab) is licensed for HER2-positive metastatic or locally recurrent unresectable breast cancer in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, in combination with trastuzumab and docetaxel.

Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone
Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone

PHARMACOLOGY 

Pertuzumab, a monoclonal antibody, targets the extracellular dimerization domain of the human epidermal growth factor 2 (HER2) protein but at a different subdomain to trastuzumab. It inhibits ligand-initated intracellular signalling, resulting in cell growth arrest and apoptosis.1

CLINICAL STUDIES

Pertuzumab was investigated in the pivotal randomised, double-blind, placebo-controlled phase III trial CLEOPATRA in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.1,2

Patients given pertuzumab, in combination with trastuzumab and docetaxel, had a median progression-free survival of 18.5 months compared with 12.4 months for those in the placebo arm (HR=0.62, 95% CI 0.52–0.75; p<0.0001).2

The most common adverse reactions reported were diarrhoea, alopecia and neutropenia.1,2

 REFERENCES

  1. Perjeta Summary of Product Characteristics, March 2013
  2. Baselga J et al. N Engl J Med 2012; 366: 109-19.

View Perjeta drug record

Further information: Roche

Follow MIMS on Twitter


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases